Literature DB >> 24922668

NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies.

Giovanni Ponti1, Davide Martorana2, Giovanni Pellacani3, Cristel Ruini3, Pietro Loschi4, Alessio Baccarani4, Giorgio De Santis4, Annamaria Pollio5, Tauro Maria Neri2, Victor Desmond Mandel3, Antonio Maiorana6, Livia Maccio6, Monia Maccaferri3, Aldo Tomasi7.   

Abstract

BACKGROUND/AIM: Von Recklinghausen disease is a syndrome characterized by a wide phenotypic variability giving rise to both, cutaneous and visceral benign and malignant neoplasms. The first include cutaneous neurofibromas, subcutaneous and plexiform neurofibromas. The latter can undergo malignant transformation and/or determine elephantiasis neuromatosa. Visceral tumors may include malignant peripheral nerve sheet tumors, gastrointestinal stromal tumors, cerebral gliomas and abdominal neurofibromas. In the present study, the authors discuss the clinical and biomolecular characterization of a cohort of 20 families with a diagnosis of type 1 neurofibromatosis. PATIENTS AND METHODS: Clinically, the cohort includes three probands with elephantiasis neuromatosa and a peculiarly high incidence of breast and gastrointestinal cancer.
RESULTS: Among the 14 NF1 mutations documented, 10 encoding for a truncated protein have been associated to particularly aggressive clinical phenotypes including elephantiasis neuromatosa, malignant peripheral nerve sheet tumors, breast cancer, gastrointestinal stromal tumors.
CONCLUSION: This effect on protein synthesis, rather than the type of NF1 mutation, is the key to the explanation of the genotype-phenotype correlations in the context of neurofibromatosis type 1. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Elephantiasis neuromatosa; GIST; NF1 truncating mutations; Neurofibromatosis type 1; malignant peripheral nerve sheet tumors; plexiform neurofibroma

Mesh:

Substances:

Year:  2014        PMID: 24922668

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Giant elephantiasis neuromatosa in the setting of neurofibromatosis type 1: A case report.

Authors:  Giovanni Ponti; Giovanni Pellacani; Davide Martorana; Victor Desmond Mandel; Pietro Loschi; Annamaria Pollio; Annarita Pecchi; Cristina Dealis; Stefania Seidenari; Aldo Tomasi
Journal:  Oncol Lett       Date:  2016-04-19       Impact factor: 2.967

2.  Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics.

Authors:  Yunpeng Liu; Justin T Jordan; Miriam A Bredella; Serkan Erdin; James A Walker; Mark Vangel; Gordon J Harris; Scott R Plotkin; Wenli Cai
Journal:  Neurology       Date:  2020-04-28       Impact factor: 9.910

3.  Genomic landscape of liposarcoma.

Authors:  Deepika Kanojia; Yasunobu Nagata; Manoj Garg; Dhong Hyun Lee; Aiko Sato; Kenichi Yoshida; Yusuke Sato; Masashi Sanada; Anand Mayakonda; Christoph Bartenhagen; Hans-Ulrich Klein; Ngan B Doan; Jonathan W Said; S Mohith; Swetha Gunasekar; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Satoru Miyano; Ola Myklebost; Henry Yang; Martin Dugas; Leonardo A Meza-Zepeda; Allan W Silberman; Charles Forscher; Jeffrey W Tyner; Seishi Ogawa; H Phillip Koeffler
Journal:  Oncotarget       Date:  2015-12-15

4.  Two Novel NF1 Pathogenic Variants Causing the Creation of a New Splice Site in Patients With Neurofibromatosis Type I.

Authors:  Vita Setrajcic Dragos; Ana Blatnik; Gasper Klancar; Vida Stegel; Mateja Krajc; Olga Blatnik; Srdjan Novakovic
Journal:  Front Genet       Date:  2019-08-22       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.